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The ubiquitin-proteasome system (UPS) is one of the major protein degradation
pathways, where abnormal UPS function has been observed in cancer and
neurological diseases. Many neurodegenerative diseases share a common pathological
feature, namely intracellular ubiquitin-positive inclusions formed by aggregate-prone
neurotoxic proteins. This suggests that dysfunction of the UPS in neurodegenerative
diseases contributes to the accumulation of neurotoxic proteins and to instigate
neurodegeneration. Here, we review recent findings describing various aspects of UPS
dysregulation in neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s
disease, and Huntington’s disease.
Keywords: ubiquitin, deubiquitinating enzyme, proteasome, Alzheimer’s disease, Parkinson’s disease,
Huntington’s disease
ABNORMAL PROTEIN AGGREGATION IN
NEURODEGENERATIVE DISEASES
Many neurodegenerative diseases are associated with aggregate-prone neurotoxic proteins
(aggresomes or inclusion bodies) that perturb cellular homeostasis and neuronal function (Popovic
et al., 2014). These diseases are also categorically classed as proteinopathies, and comprise
aggregation-prone components such as β-amyloid (Aβ) and tau in Alzheimer’s disease (AD),
α-synuclein in Parkinson’s disease (PD), and polyglutamine (polyQ) repeat diseases.
Alzheimer’s disease is the most common form of progressive neurodegeneration and represents
the main cause of senile dementia affecting about 10% of the population over the age of 65
and about 50% of the population over 85. AD can be divided into two forms: familial AD and
sporadic AD. Familial AD accounts for 5%∼10% of AD patients, where inherited autosomal
dominant mutations in three genes have been considered as the primary causes of familial
AD: these include mutations in the genes encoding β-amyloid precursor protein (APP) and
presenilins (PS1 and PS2; Goate et al., 1991; Levy-Lahad et al., 1995; Sherrington et al., 1995).
In addition, sporadic AD is associated with polymorphisms in the Apolipoprotein E (APOE)
gene, where the epsilon four allele is a strong genetic risk factor for late-onset AD (Strittmatter
et al., 1993; Bu, 2009; Fu et al., 2016). Accumulation and aggregation of neurotoxic proteins,
such as β-amyloid (Aβ), hyperphosphorylated tau, ubiquitinated proteins, and other unfolded
proteins in vulnerable brain regions such as the hippocampus and cortex in AD brain is central
to disease pathogenesis (Selkoe, 2001). Two major pathological hallmarks in AD are extracellular
amyloid plaques and intraneuronal neurofibrillary tangle (NFT; Zhang et al., 2011). NFTs are
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comprised of hyperphosphorylated microtubule-associated
protein tau (Song et al., 2015; Yamada et al., 2015; Zempel and
Mandelkow, 2015). Amyloid plaques are primarily comprised of
Aβ which is derived from sequential cleavages of APP by β- and
γ-secretases (Zhang et al., 2011; Audrain et al., 2016). Cumulative
evidence demonstrates that Aβ and tau are neurotoxic and can
trigger a cascade of neurodegenerative processes ending in
neuronal death, suggesting that overproduction/accumulation of
Aβ and tau in vulnerable brain regions is the primary influence
driving AD pathogenesis (Hardy and Selkoe, 2002; Gautam et al.,
2015; Golovyashkina et al., 2015; Popugaeva et al., 2015).
Parkinson’s disease is the second most common
neurodegenerative disease, clinically characterized by motor
abnormalities, including resting tremor, rigidity, hypokinesia,
and postural instability (Dauer and Przedborski, 2003; More and
Choi, 2015). The loss of dopaminergic neurons in the substantial
nigra subregion of midbrain is the major cause of motor deficits
(Chen et al., 2015). Major pathological features of PD include
intraneuronal accumulation of Lewy bodies and dystrophic
neurites (Lewy neurites), both of which comprise aggregated
proteins, such as α-synuclein, parkin, and ubiquitinated proteins
(Hughes et al., 1992; Braak et al., 2003; Chiasserini et al., 2015;
Xiang et al., 2015). Sporadic PD accounts for more than 90% of
PD cases (Lang and Lozano, 1998), and only less than 10% of
familial PD cases are caused by monogenic mutations (Benitez
et al., 2016). Mutations in the gene encoding α-synuclein
(Polymeropoulos et al., 1997; Helferich et al., 2015; Majbour
et al., 2016; Schonherr et al., 2016) represent autosomal dominant
familial PD, and mutations in genes encoding parkin (Kitada
et al., 1998; Cha et al., 2015), UCHL1 (Leroy et al., 1998;
Maraganore et al., 1999), DJ-1 (Bonifati et al., 2003), PINK1
(Valente et al., 2004), and LRRK2 (Zimprich et al., 2004; Saha
et al., 2015) cause autosomal recessive familial PD.
Huntington’s disease (HD) is an autosomal dominant
progressive neurodegenerative disorder, clinically characterized
by cognitive impairment, chorea and dystonia, bradykinesia,
uncoordinated movement, mood disorder and other psychiatric
symptoms, and behavioral difficulties (Huntington Study Group,
1996). As the most common of the polyQ disorders, HD is
caused by expansion of a CAG repeat coding for polyQ in
the N-terminus of the huntingtin protein (MacDonald et al.,
1993; Evers et al., 2015; Nekrasov et al., 2016). There is a
remarkable repeat length threshold effect, where polyQ chain
expansion of 36 repeats triggers HD onset, whereas repeats of
less than 35 are non-pathological (Chong et al., 1997). The polyQ
expansion in the N-terminus of huntingtin protein confers a
gain-of-function phenotype, and is associated with significant
neurotoxicity (Tallaksen-Greene et al., 2003).
In addition to huntingtin, expansion of polyQ-encoding CAG
repeats in several genes have also been found in other polyQ
repeat diseases, such as Ataxin-1 in spinocerebellar ataxia type
1 (SCA1), Ataxin-2 in SCA2, Atantin-3 in SCA3, α1A-voltage-
dependent calcium channel (CACNA1A) in SCA6, Ataxin-7
in SCA7, Atrophin-1 in dentatorubral-pallidoluysian atrophy
(DRPLA), and androgen receptor in SBMA (Zoghbi and Orr,
2000; Del Cano-Espinel et al., 2015). All polyQ repeat disorders
are dominant neurodegenerative diseases and are associated with
pathological intracellular inclusion bodies in the affected brain
regions (Ross et al., 1997; Zoghbi and Orr, 2000).
UBIQUITIN-PROTEASOME SYSTEM
Ubiquitin is an evolutionarily conserved 76-amino acid moiety
covalently tandemly linked to target protein components
for degradation by the ubiquitin-proteasome system (UPS),
and is required for degradation of about 80% intracellular
proteins in eukaryotes (Pickart, 2001). The presence of
ubiquitin in intracellular inclusions has been found in various
neurodegenerative diseases, for example, amyloid plaques and
NFT in AD, Lewy bodies in PD, and intranuclear inclusions in
polyQ disorders (Todi and Paulson, 2011).
Protein ubiquitination occurs through the coordinated activity
of several enzymes, including an ubiquitin activating enzyme (E1
ligase), conjugating enzyme (E2 ligase), and E3 ligase. Initially,
a single ubiquitin moiety is attached to an active-site Cysteine
residue within the E1 ligase through a thioester bond in an ATP
dependent manner. The activated ubiquitin is then transferred to
an ubiquitin conjugating enzyme-E2 ligase. Finally, the E2 ligase
will cooperatively transfer the ubiquitin chain with a specified E3
ligase to a particular substrate, whereby the 26S proteasome will
target the polyubiquitinated protein for degradation (Figure 1).
Ubiquitin E3 ligases determine the specificity of
ubiquitination process. E3 ligases are grouped into three classes
according to their unique domains, including Really Interesting
New Gene (RING) or U-box domain-containing E3 ligases,
Homologous to E6AP C-terminus (HECT) domain-containing
E3 ligases, and RING-between-RING (RBR) domain-containing
E3 ligases (Atkin and Paulson, 2014; Morreale and Walden,
2016). RING E3 ligases catalyze the transfer of ubiquitin directly
from E2 ligases to the substrates by binding both of them.
Whereas HECT E3 ligases comprise a conserved Cysteine
residue as an ubiquitin acceptor, where the activated ubiquitin is
initially transferred from the E2 ligases to HECT E3 ligases prior
to E3-mediated substrate conjugation (Ravid and Hochstrasser,
2008). Unlike RING E3 ligases, RBR E3 ligases contain two RING
domains (RING1 and RING2) separated by an in-between-RING
(IBR) domain. Functionally, RBR E3 ligases are similar with
HECT E3 ligases, both catalyze ubiquitin first transfer from E2
ligases to a catalytic Cysteine residue on E3 ligases then from the
E3 ligases to the substrates (Spratt et al., 2014) (Figure 1).
The fate of an ubiquitin-linked protein is dependent on
Lysine chain-specific polyubiquitination (Grabbe et al., 2011;
Kulathu and Komander, 2012; Rieser et al., 2013). For example,
Lys48-linked polyubiquitin chains usually target proteins for
degradation (Husnjak et al., 2008), whereas Lys63-linked
polyubiquitination is involved in regulation of NFκB signaling
(Laplantine et al., 2009), Lys27-linked polyubiquitin chains are
important for mitophagy (Geisler et al., 2010), and Lys11-linked
polyubiquitination is implicated in cell cycle regulation (Bremm
and Komander, 2011). Therefore, ubiquitination is not only
important for protein degradation, but is also implicated in
non-proteolytic functions, such as endocytosis, protein-protein
interaction, intracellular trafficking, inflammatory signaling,
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FIGURE 1 | Ubiquitination and ubiquitin-proteasome system. Ubiquitination is a posttranslational modification that the ubiquitin is covalently conjugated to a
Lysine residue of the substrate proteins. Ubiquitin is first attached to a Cysteine residue (the active-site) of ubiquitin activating enzyme (E1 ligase) in an
ATP-dependent reaction. Subsequently, the activated ubiquitin will be transferred to a Cysteine residue of conjugating enzyme (E2 ligase). Finally, working with a
specific E3 ligase, E2 ligase can transfer the (poly)ubiquitin to a Lysine residue of the substrate. There are three major classes of E3 ligases, including RING E3
ligases, HECT E3 ligases, and RBR E3 ligases. RING E3 ligases catalyze the transfer of ubiquitin directly from E2 ligases to the substrate. However, the activated
ubiquitin is first transferred from E2 ligases to HECT or RBR E3 ligases and then be transferred to the substrate from the E3 ligases. Lys48-linked polyubiquitin
chains usually target proteins for proteasomal degradation, whereas Lys63-linked polyubiquitination is involved in regulation of NFκB signaling. Lys27-linked
polyubiquitination is important in regulating mitophagy, and Lys11-linked polyubiquitin chains are implicated in cell cycle regulation. Ubiquitination is reversed by
deubiquitinating enzymes (DUBs). DUBs are crucial for determining the fate of ubiquitinated proteins through removing/editing the length/type of polyubiquitin chains.
In addition, DUBs can disassemble unanchored ubiquitin chains for ubiquitin recycling.
autophagy, and DNA repair (Grabbe et al., 2011; Kulathu and
Komander, 2012; Rieser et al., 2013).
The UPS is involved in protein quality control and removal of
misfolded and aggregated proteins, and dysfunction of the UPS
is implicated in the pathogenesis of neurodegenerative diseases
(Popovic et al., 2014).
DEUBIQUITINATING ENZYMES
The process of ubiquitination is reversible and the reverse
process is called deubiquitination which is accomplished by
deubiquitinating enzymes (DUBs; Rubinsztein, 2006; Reyes-
Turcu et al., 2009; Popovic et al., 2014). Increasing evidence
indicates the importance of DUBs in regulating UPS function,
including proofreading ubiquitin-protein conjugates, removing
ubiquitin from conjugated proteins as key examples (Amerik
and Hochstrasser, 2004) (Figure 1). Pivotal roles for DUBs
have been demonstrated in maintaining neuronal functions
and regulating the pathogenesis of various neurodegenerative
diseases (Rubinsztein, 2006; Todi and Paulson, 2011; Popovic
et al., 2014).
More than 100 DUBs have been identified (Popovic et al.,
2014), and can be subdivided into five subfamilies. DUBs
can be further categorized into two classes, the Cysteine
proteases and the zinc-dependent metalloproteases (Todi and
Paulson, 2011). Cysteine protease-associated DUBs include
the ubiquitin carboxyl-terminal hydrolases (UCHs), ubiquitin
specific proteases (USPs), Machado Joseph Diseases (MJD)
proteases, and ovarian tumor (OTU) protease. Metalloprotease
DUBs comprise the JAB1/MPN/Mov34 metalloenzyme (JAMM)
subfamily.
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UCHL1, a member of the UCH subfamily, is one of the most
abundant proteins in the brain. UCHL1 is known to interact
with and stabilize monomeric ubiquitin, and facilitates the E3
ligase activity in its dimeric form (Doran et al., 1983; Wilkinson
et al., 1989). An Aplysia UCHL1 ortholog, ubiquitin carboxyl-
terminal hydrolase (AP-Uch) has been found to be important
in maintaining synaptic function (Hegde et al., 1997). Inhibiting
the expression or function of AP-Uch blocks induction of long-
term facilitation, which is thought to be the molecular basis
for learning and memory (Hegde et al., 1997). Mammalian
UCHL1 is required for normal synaptic structure and function
in hippocampal neurons (Cartier et al., 2009). Activation of
NMDA receptor upregulates UCHL1 activity and the levels
of free ubiquitin monomers. Inhibition of UCHL1 disrupts
distribution of synaptic proteins, increases dendritic spine size
and reduces spine density. However, restoration of ubiquitin in
UCHL1-inhibited neurons rescues impaired synaptic structure
(Cartier et al., 2009). UCHL1 is also essential for normal structure
and function of neuromuscular junctions (NMJs), reduction of
synaptic vesicles and accumulation of tubulovesicular structures
at the presynaptic nerve terminals have been observed in Uchl1
knockout mice (Chen et al., 2010). UCHL3, a homolog of
UCHL1, is involved in spatial and working memory (Wood et al.,
2005).
19S proteasome-associated DUBs comprise three members:
USP14, UCH37, and RPN11, which show differences in ubiquitin
chains removals and consequent protein degradation (Lee
et al., 2011). It has been reported that both USP14 and
UCH37 prevent substrate degradation by removing ubiquitin
chains and promoting proteasomal substrate dissociation. In
contrast, RPN11 cleaves at the base of the ubiquitin-linked
substrates and promotes substrate degradation (Lee et al.,
2011). USP14 is essential for synaptic development and normal
function of NMJs (Chen et al., 2009), which is mediated
through ubiquitination and activation of c-Jun N-terminal kinase
signaling (Vaden et al., 2015). Pharmacological inhibition of
USP14 enhances proteasomal degradation of several neurotoxic
proteins, including tau, TDP14, and Ataxin-3 (Lee et al.,
2010). Usp14-deficient mice display motor neuron deficits
and developmental NMJ defects (Chen et al., 2009). USP16,
a chromosome 21-encoded gene, is involved in chromatin
remodeling and cell cycle progression through regulated
ubiquitination of histone H2A (Joo et al., 2007). USP16
interacts with HERC2 and modulates the ubiquitination in
DNA repair machinery components (Zhang et al., 2014).
USP16 is upregulated in Down’s syndrome (DS) cells due to
extrachromosomal triplication in trisomy 21, downregulation
of USP16 partially restores the impaired proliferation in
DS somatic stem cells (Adorno et al., 2013). It has been
reported that USP16 acts as a H2A DUB and regulates
hematopoiesis and hematopoietic stem cell function (Gu
et al., 2016). Moreover, USP16 is required for embryonic
stem cell differentiation, where USP16 deficiency leads to
embryonic lethality in mouse deletion models (Yang et al.,
2014).
The gene encoding USP25 also resides on human
chromosome 21 (Valero et al., 1999), USP25 is involved in
protein degradation by the 26S proteasome (Valero et al., 1999).
USP25 is also implicated in inflammation, and it has been found
to facilitate removal of Lys63-linked ubiquitin chains from
tumor necrosis factor-receptor associated factor 5/6 (TRAF5/6),
Usp25-deficient mice show higher sensitivity to IL-17 dependent
inflammation and autoimmunity (Zhong et al., 2012).
DYSREGULATION OF UBIQUITINATION
IN NEURODEGENERATIVE DISEASES
Accumulating evidence indicates that dysfunction of the UPS
is a key factor to initiate and aggravate the pathogenesis
of neurodegenerative diseases. We will focus on the
dysregulation of ubiquitination and proteasomal degradation in
neurodegenerative pathology in AD, PD, and HD (Table 1).
Dysregulation of the UPS in Alzheimer’s
Disease
The presence of ubiquitin in NFTs and amyloid plaques in
AD brain has been described as early as 1987 (Cole and
Timiras, 1987; Mori et al., 1987; Perry et al., 1987). Ubiquitin-
targeted proteasomal activity declines with age Tg2576 AD
mouse model brain, and Aβ treatment markedly attenuates
proteasomal activity in cultured neurons (Oh et al., 2005). Aβ
induced UPS dysfunction contributes to the accumulation of
reticulon 3 (RTN3) in dystrophic neurites, and the presence
of dystrophic neurites and clustering of tubular endoplasmic
reticulum has been observed in RTN3 transgenic mouse
brain (Hu et al., 2007; Sharoar et al., 2016). Interestingly,
intracellular Aβ accumulation and impaired proteasome function
can be reversed by the ubiquitin E3 ligase parkin (Rosen
et al., 2010). Parkin expression is downregulated in AD
brains, and reduced parkin expression may contribute to the
accumulation of intracellular Aβ. Moreover, parkin expression
results in Aβ reduction which can be dampened by proteasome
inhibitors (Rosen et al., 2010). In addition, overexpression
of parkin in APP/PS1 mouse models restores impaired long-
term potentiation (LTP) and rescues behavioral abnormalities
by reducing Aβ load and neuroinflammation (Hong et al.,
2014).
UCHL1 has been observed in ubiquitin-enriched inclusion
bodies in AD brains (Lowe et al., 1990). In addition, decreased
soluble UCHL1 protein levels was detected in the brains of
postmortem AD patients and APP/PS1 mouse models (Choi
et al., 2004; Gong et al., 2006), and soluble UCHL1 is inversely
proportional to the number of NFTs in AD brains (Choi
et al., 2004). Upregulation of UCHL1 improves contextual
learning and restores synaptic functions in APP/PS1 mouse
models, where rescue effects are dependent on enzymatic
UCHL1 activity (Gong et al., 2006). Moreover, overexpression
of UCHL1 reduces the levels of β-secretase BACE1, and
consequent BACE1 cleavage products (APP C-terminal fragment
C99 and Aβ). Depletion of UCHL1 increases the levels of
BACE1, C99, and Aβ in the Uchl1-null gad mice (Zhang et al.,
2012).
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TABLE 1 | Ubiquitin-proteasome system is implicated in neurodegenerative diseases pathogenesis.
Disease Protein Disease Relevance Pathogenesis Reference
AD Parkin (E3 ligase) Decreased in AD Parkin overexpression reduces Aβ and restores
impaired LTP and behavioral abnormalities of
APP/PS1 mouse model.
Rosen et al., 2010; Hong et al., 2014
AD UCHL1 (DUB) Decreased in AD UCHL1 overexpression improves contextual
memory and restores synaptic functions of
APP/PS1 mouse model.
Choi et al., 2004; Gong et al., 2006
AD HRD1 (E3 ligase) Decreased in AD HRD1 reduces Aβ generation through interacting
with APP and facilitating APP ubiquitination and
proteasomal degradation.
Kaneko et al., 2010
AD CHIP (E3 ligase) Upregulated in AD CHIP ubiquitinates phosphorylated tau. Deletion
of CHIP leads to the accumulation of
non-aggregated, hyperphosphorylated, as well as
caspase-3-cleaved tau species.
Overexpression of CHIP and Hsp70/90 decreases
the steady-state Aβ levels and promotes Aβ
degradation.
Petrucelli et al., 2004; Shimura et al., 2004;
Dickey et al., 2006, 2007; Kumar et al., 2007
PD Parkin (E3 ligase) Decreased in PD with
loss-of-function mutations
More than 100 different PARK2 (encoding parkin)
mutations have been found in PD patients,
including missense, truncation, copy number
variations, deletions, and insertions.
Loss-of-function mutations in parkin impair its E3
ligase activity and lead to the accumulation of
α-synuclein and the formation of Lewy bodies.
Shimura et al., 2001; Lesage and Brice, 2009;
Lu et al., 2009; Chung et al., 2013
PD UCHL1 (DUB) Mutation on I93M and
S18Y.
UCHL1I93M mutation promotes its dimerization
and inhibits the proteasomal degradation of
α-synuclein through the Lys63-linked
polyubiquitination of α-synuclein.
Leroy et al., 1998; Liu et al., 2002; Maraganore
et al., 2004; Setsuie et al., 2007
PD CHIP (E3 ligase) NA CHIP can enhance parkin’s E3 ligase activity.
Moreover, CHIP ubiquitinates LRRK2 and
α-synuclein and promotes their degradation.
Imai et al., 2002; Ko et al., 2009; Kalia et al.,
2011
PD TRAF6 (E3 ligase) Upregulated in PD TRAF6 promotes Lys6-, Lys27-, and Lys29-linked
ubiquitination of DJ-1 and α-synuclein. TRAF6
induces Lys63-linked ubiquitination of PINK1, and
stabilizes PINK1 on the depolarized mitochondria.
Zucchelli et al., 2010; Chung et al., 2013;
Murata et al., 2013
HD CHIP (E3 ligase) NA CHIP suppresses aggregation and toxicity of
polyQ-huntingtin. Knockdown of CHIP in HD
transgenic mice aggravates disease pathology.
Miller et al., 2005
SCA3 Ataxin-3 (E3 ligase) Gain-of-function mutation
with polyQ expansion
Ataxin-3 overexpression protects Drosophila from
polyQ-huntingtin-induced neurodegeneration.
MJD-linked Ataxin-3 mutations promote
ubiquitination and autophagic degradation of
parkin.
Warrick et al., 2005; Durcan et al., 2011
A direct interaction between APP and ubiquitin ligases
also contributes to amyloid pathology. HRD1, an endoplasmic
reticulum-associated degradation (ERAD) ubiquitin E3 ligase,
is reduced in AD brains (Kaneko et al., 2010). HRD1
interacts with APP through its Proline-rich region, and this
interaction reduces Aβ generation through promoting APP
ubiquitination and degradation (Kaneko et al., 2010). In addition,
APP can bind to ubiquitin E3 ligases Stub1 and CRL4CRBN
through the APP cytosolic region (ACR; Del Prete et al.,
2016). ACR promotes the ubiquitination of several presynaptic
proteins and regulates neurotransmitter release (Del Prete et al.,
2016).
Polyubiquitinated tau has also been found in the brains of
AD patients (Perry et al., 1987), where ubiquitin conjugation
usually occurs at Lys254, Lys311, and Lys353 within the tau
microtubule-binding domain (Cripps et al., 2006). In AD brains,
accumulation of hyperphosphorylated, ubiquitinated tau protein
has been found at both presynaptic and postsynaptic terminals,
which is associated with dysfunction of the UPS (Tai et al., 2012).
Recently, Myeku et al. reported that tau can induce dysfunction
of the 26S proteasome which can be prevented by activating
cAMP-PKA signaling. Protective effects derived from cAMP-
PKA signaling are mediated through phosphorylation of the 26S
proteasomal subunit (Myeku et al., 2016). Han et al. directly
delivered purified proteasomes into cells through mesoporous
silica nanoparticle-mediated endocytosis, and they found that
extraproteasomal transfer reduces tau aggregates and promotes
cell survival against tau-induced proteotoxic stress (Han et al.,
2014). C-terminus of Hsp70-interacting protein (CHIP), an
ubiquitin E3 ligase, is also implicated in AD pathogenesis. It has
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been found that both CHIP and Hsp70 are upregulated in the
brains of AD patients (Sahara et al., 2005). CHIP and its binding
protein Hsp70 can induce the ubiquitination and degradation
of phosphorylated tau (Petrucelli et al., 2004; Shimura et al.,
2004), deletion of CHIP leads to the accumulation of non-
aggregated, hyperphosphorylated, as well as caspase-3-cleaved
tau (Dickey et al., 2006). Moreover, inhibition of Hsp90 reduces
hyperphosphorylated tau through an interaction with CHIP
(Dickey et al., 2007). In addition, overexpression of CHIP and
Hsp70/90 decreases steady-state Aβ levels and promotes Aβ
degradation (Kumar et al., 2007).
Dysregulation of UPS in Parkinson’s
Disease
The presence of ubiquitin-immunopositive Lewy bodies in the
brains of PD patients has been observed about 30 years ago
(Kuzuhara et al., 1988). Impaired proteasomal function in the
substantia nigra of PD brains was later observed (McNaught
and Jenner, 2001). Importantly, genetic evidence reveals a clear
involvement of UPS dysfunction in PD pathogenesis: familial
PD-associated genetic variations have been identified on PARK2
(Kitada et al., 1998) and UCHL1 (Leroy et al., 1998; Maraganore
et al., 1999), which encode the ubiquitin E3 ligase parkin and
deubiquitinating enzyme UCHL1, respectively. Recessive early-
onset familial PD can also be caused by mutations in genes
encoding DJ-1 (Abou-Sleiman et al., 2003; Bonifati et al., 2003)
and PINK1 (Valente et al., 2004), presumably through a loss-of-
function mechanism.
An interaction between parkin and its substrate α-synuclein
is a crucial regulatory component of dopaminergic neuron
degeneration, loss-of-function mutations in PARK2 usually
cause early-onset autosomal recessive PD (Kitada et al., 1998),
whereas disease-associated mutations in α-synuclein are usually
associated with autosomal dominant PD (Polymeropoulos et al.,
1997). Mutant parkin fails to interact with α-synuclein, leads
to the accumulation of α-synuclein and the formation of
Lewy bodies (Shimura et al., 2001). Transgenic mice carrying
mutant parkinQ311X develop progressive hypokinetic motor
deficits, accumulation of α-synuclein and age-dependent loss of
dopaminergic neurons in the substantia nigra and striatum (Lu
et al., 2009).
Parkin is an E3 ligase mediating multiple forms of
ubiquitination, including monoubiquitination, Lys48- and
Lys63-linked polyubiquitination (Moore, 2006). In addition,
parkin can form an E3 ligase complex with PINK1 and DJ-1 to
promote unfolded protein degradation (Xiong et al., 2009): PD
mutations in each component impair E3 ligase activity (Xiong
et al., 2009). CHIP can promote parkin-mediated ubiquitination
of Pael receptor and inhibit the Pael receptor-induced cell death
(Imai et al., 2002). In addition, CHIP ubiquitinates and facilitates
proteasomal degradation of LRRK2, where knockdown of CHIP
exacerbates neurotoxicity mediated by mutant LRRK2 (Ko et al.,
2009). CHIP can ubiquitinate α-synuclein and reduce toxic
α-synuclein oligomers (Kalia et al., 2011). TRAF6 is upregulated
in the brains of PD patients (Chung et al., 2013), and TRAF6
promotes Lys6-, Lys27-, and Lys29-linked ubiquitination of
DJ-1 and α-synuclein. This interaction may cause aggregation of
insoluble and polyubiquitinated mutant DJ-1 proteins (Zucchelli
et al., 2010). Moreover, TRAF6 ubiquitinates PINK1 at Lys433
residue as a poly-Lys63 conjugated form which stabilizes PINK1
in depolarized mitochondria. Down-regulation of TRAF6
disrupts PINK1 localization, thereby causing mitochondria
damage through parkin recruitment (Murata et al., 2013).
Mutations in UCHL1 have been reported in rare cases of
early-onset familial PD (Leroy et al., 1998; Maraganore et al.,
1999). Most notably, the UCHL1I93M PD variant shows reduced
deubiquitinating activity (Leroy et al., 1998). Ubiquitin-positive
inclusion bodies and the loss of dopaminergic neurons have been
observed in the substantia nigra of UCHLI93M transgenic mouse
brains (Setsuie et al., 2007). In addition, UCHL1I93M mutation
promotes dimerization and Lys63-linked polyubiquitination of
α-synuclein. Lys63-linked polyubiquitination may aggravate PD
pathology by inhibiting proteasomal degradation of α-synuclein
(Liu et al., 2002).
Dysregulation of UPS in Huntington’s
Disease
HD patients manifest polyQ repeats of over 40 residues within
the N-terminus of huntingtin protein. Ubiquitin-linked mutant
huntingtin has been found in neuronal intranuclear inclusions
and dystrophic neurites in the cortex and striatum of HD
patients (Difiglia et al., 1997). However, it seems that eukaryotic
proteasomes fail to cleave and eliminate pathogenic protein
species with repeats greater than 25Q residues; this results
in accumulation and aggregation of huntingtin protein in
the neuronal nucleus (Venkatraman et al., 2004). However,
it has been reported that a selective histone deacetylase
(HDAC) inhibitor 4b ameliorates cognitive impairment in
N171-82Q HD mouse model by preventing formation of
nuclear huntingtin aggregates. Mechanistically, HDAC inhibition
upregulates expression of multiple genes that are fundamental
to protein phosphorylation and ubiquitination, including Ube2K,
Ubqln, Ube2e3, Usp28, Sumo2, as well as the genes encoding
components of the inhibitor of κB kinase (IKK) complex (Jia
et al., 2012). It has been reported that CHIP suppresses polyQ
aggregation and toxicity, and knockdown of CHIP in HD
transgenic mice aggravated disease pathology (Miller et al., 2005).
Spinocerebellar ataxia type 3 (SCA3) is another polyQ
repeat disease, which is caused by a polyQ-encoding CAG
repeat expansion in the gene encoding Ataxin-3 (Kawaguchi
et al., 1994). SCA3 is characterized by progressive ataxia with
degeneration in the cerebellum, brain stem, substantia nigra,
and globus pallidus interna. Clinical symptoms of SCA3 include
impaired eye movement, speech and swallowing defects (Todi
and Paulson, 2011). Ataxin-3 is a DUB from MJD subfamily of
proteases which contain an ubiquitin interacting motif flanking
the polyQ domain. Ataxin-3 preferentially cleaves Lys63 linkages
in polyubiquitinated chains containing both Lys48 and Lys63
linkages (Winborn et al., 2008). Overexpression of normal
human Ataxin-3 can protect Drosophila from polyQ-huntingtin-
induced neurodegeneration (Warrick et al., 2005). Unlike wild-
type Ataxin-3, MJD-linked mutant Ataxin-3 can promote
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ubiquitination and autophagic degradation of parkin probably
through regulating the levels of Lys27- and Lys29 ubiquitin-
linked parkin (Durcan et al., 2011).
CONCLUSION
Although UPS-mediated protein degradation has been well-
studied in the last few decades, regulation of ubiquitination
and proteasomal degradation in normal brain function and
pathogenesis of neurodegenerative diseases remains largely
unknown. The regulation of polyubiquitination processes may
vary at different physiological and/or pathologic conditions.
This review surveyed dysregulation of UPS in several major
neurodegenerative diseases, more research is required to
understand how the UPS is disrupted in neurodegenerative
pathogenesis. By enriching our understanding of protein
degradation, we can begin to formulate strategies to treat
neurodegenerative diseases remediating aspects of UPS
dysregulation.
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